Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 30 | 2021GILD: Q1 2021 Earnings Call Summary; JNJ: Cilta-cel MAA SubmittedAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 29 | 2021BMY: Q1 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Apr 27 | 2021Kymriah's Sales Continue to Grow; Novartis Q1 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Apr 26 | 2021Thoughts on BMS’s New Abecma Ph1/2 KarMMa-7 Basket Combination TrialAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Apr 23 | 2021BMS Announces New EU Manufacturing Site in the Netherlands; AUTO4 (TRBC1 CAR-T) Receives Innovation Passport and ILAP Designation; Allogene’s ALLO-715 Receives RMAT Designation by the FDA; No Major Updates in April's CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Apr 22 | 2021Yescarta Reimbursement in Japan Matched to Kymriah’s Latest Price Adjustment; Will Breyanzi be Priced Similarly?Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Apr 21 | 2021Humanigen Cancels Collaboration with Gilead (Kite) to Test Lenzilumab with Other Commercial CD19 CAR-Ts; FDA Accepts Allogene’s TurboCAR ALLO-605 (BCMA CAR-T) IND; First Patient Dosed with Ziopharm’s RPM CD19 CAR-T in Taiwan; No Regulatory Updates for Cilta-cel in JNJ’s Q1 2021 Earnings CallAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CD19 Apr 20 | 2021Precision Regains Control of Their Allogeneic CAR-T Pipeline and Shifts Focus to their Stealth Cell Program; Alan List Joins Precision as CMOAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR Apr 16 | 2021Latest Advances Targeting Neoantigens and Developing TCR-T Cell Therapies; Ziopharm Presents Preclinical Data from Their Hotspot TCR-T Library Program; Medigene’s PRAME-Specific TCR PD1-41BB Switch Receptor Could Treat a Broad Range of Liquid and Solid Tumors; AACR 2021 Day 6Access Free BlastFree
Posted in: BCMA, CD19 Apr 15 | 2021Latest NK Cell Therapy Advances Discussed in a Panel Session; Fate Tx Presents Preclinical Updates for Two iPSC-derived CAR-NKs; AACR 2021 Day 5Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Apr 14 | 2021Switchable CAR-T Updates from Arcellx, GEMoaB, and AbClon; Carisma Therapeutics Presents Their CAR-Macrophage and CAR-Monocyte Programs; AACR 2021 Day 4Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 13 | 2021Gilead Reports Innovative Biomarkers Associated with Clinical Outcomes in the Ph2 ZUMA-5 Trial; Carl June Explores Novel Approaches to Improve CAR-T Function; IL-2 Makes a Comeback with OrthoCARs; AACR 2021 Day 3Access Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T Apr 13 | 2021First Patient Dosed in Allogene’s ALLO-715 + Nirogacestat Cohort in the Ph1 UNIVERSAL TrialAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Apr 12 | 2021Can Allogene’s PD1 TurboCAR Overcome the TME? CRISPR Tx’s CTX130 CD70 KO Prevents CAR-T Exhaustion; Can TCR2’s CD70 and Allogeneic TRuC-Ts Outclass CAR-T Therapies? AACR 2021 Day 2Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, TCR Apr 11 | 2021Novel In-depth Product Characteristics for Kymriah and Yescarta Correlate with Patient Outcomes; Gracell’s Clinical Update for GC027 TruUCAR in T-ALL; Preliminary Results for TCR2’s Gavo-cel in Mesothelin Overexpressing Solid Tumors; AACR 2021 Day 1Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Apr 09 | 2021Gilead Files Tecartus’s sBLA in Adult R/R ALL; AUTO1 Receives PRIME Designation by the EMA; JNJ / Legend Complete Cilta-cel’s Rolling BLA in the US; BMS Files Abecma in Japan for R/R MM; Precision’s New CEO Transition PlanAccess Free Blast
Free
Posted in: CAR-T, CD19 Mar 31 | 2021Autolus Pivots Manufacturing Away from the US; TCR2 Takes Over Autolus’s Rockville Facility; Is Confidence in AUTO1 Wavering?Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Mar 29 | 2021First BCMA CAR-T Approved in the US for Multiple Myeloma; Will Abecma’s 33-day TAT and High Price Prevent Wide-Spread Adoption?Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Mar 27 | 2021Ide-cel Approved by FDA as Abecma in r/r MM After Four Lines of Previous TherapyAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Mar 25 | 2021Breyanzi Approved in Japan; but What's the Price?Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.